Verge Genomics Utilizes Failed ALS Clinical Trial Data for New AI Benchmark
Verge Genomics, a company focused on developing treatments for neurodegenerative diseases, plans to convert data from its recently failed Phase 1b clinical trial for an ALS drug into a new artificial intelligence (AI) benchmarking dataset. Co-founded by Alice Zhang, the company aims to extract valuable insights from the trial's challenges, particularly the high patient dropout rate due to drug intolerance. This initiative underscores Verge Genomics' commitment to sharing learnings from unsuccessful trials to benefit the broader field of neurology and drug development.
Verge Genomics, co-founded by Alice Zhang over a decade ago, was established with the goal of identifying superior drugs for neurodegenerative conditions such as Parkinson's, ALS, and Alzheimer's by analyzing gene networks.
The company has engaged in target discovery, leading to Eli Lilly nominating two targets to its internal pipeline in 2024. Verge Genomics also developed its own pipeline, including an ALS drug that recently underwent a Phase 1b clinical trial.
However, this trial failed last month, with approximately one-third of the patients discontinuing treatment due to drug intolerance. Following the trial's outcome, Verge Genomics published a postmortem detailing the issues encountered.
Alice Zhang emphasized the importance of transparency, stating that while there is often a temptation to avoid discussing trials that do not meet anticipated endpoints, sharing these learnings is crucial for the field of ALS research and beyond. The company intends to repurpose the data from this unsuccessful trial to create a new AI benchmarking dataset.
(Source: STAT News)
